Vascular Interventional Advances (VIVA)

The VIVA Foundation is a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration. It hosts the VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) annual conferences. The VIVA Foundation also presents the Vascular Leaders Forum and collaborates with other industry-leading groups to move the field forward. 

RSS icon
The Abbott Esprit BTK everolimus-eluting biosorbable scaffold system for below the knee peripheral artery disease on display at TCT 2024. Photo by Dave FornellTCTn 2024 DF

Bioresorbable BTK stent superior to ballon angioplasty at 2 years

Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.

Shockwave Javelin Peripheral IVL Catheter

Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients

Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.

Medtronic’s IN.PACT Admiral DCBs

Drug-coated balloons an effective tool in the battle against femoropopliteal disease

Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes. 

Thumbnail

Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients

The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas. 

Many PAD patients are missing out on vital risk assessments

The findings, based on Medicare data, were presented at VIVA21 in Las Vegas.

Arizona patients successfully receive the world’s first bioconvertible IVC filter commercially offered in US

BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter.

New Data Continue to Reinforce IN.PACT Admiral DCB as a Durable, Frontline Option to Address Treatment Challenges in PAD

Medtronic data presented today reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries.

The Eluvia drug-eluting stent continues to demonstrate positive outcomes in long lesion IMPERIAL sub-study

Boston Scientific announced clinical outcomes from the IMPERIAL Long Lesion Sub-study demonstrating that the Eluvia Drug-Eluting Vascular Stent System is safe and effective in treating patients with long, complex, calcified lesions within the superficial femoral and proximal popliteal arteries.

Displaying 1 - 8 of 26

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.